Worth Venture Partners LLC Reduces Stock Position in Vaccinex, Inc. (NASDAQ:VCNX)

Worth Venture Partners LLC lessened its position in shares of Vaccinex, Inc. (NASDAQ:VCNXFree Report) by 8.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 654,079 shares of the company’s stock after selling 63,480 shares during the quarter. Worth Venture Partners LLC owned 5.24% of Vaccinex worth $435,000 at the end of the most recent reporting period.

Separately, Armistice Capital LLC purchased a new stake in shares of Vaccinex in the third quarter worth about $768,000. Institutional investors own 50.11% of the company’s stock.

Vaccinex Stock Up 3.5 %

Shares of VCNX traded up $0.19 during mid-day trading on Wednesday, reaching $5.59. The company had a trading volume of 1,091 shares, compared to its average volume of 10,387. Vaccinex, Inc. has a 52-week low of $4.43 and a 52-week high of $100.80. The stock has a market capitalization of $8.83 million, a P/E ratio of -0.07 and a beta of 0.74. The stock has a 50 day moving average of $6.41 and a two-hundred day moving average of $8.48.

Vaccinex (NASDAQ:VCNXGet Free Report) last issued its earnings results on Tuesday, April 2nd. The company reported ($39.40) EPS for the quarter.

Vaccinex Profile

(Free Report)

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.

Recommended Stories

Want to see what other hedge funds are holding VCNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaccinex, Inc. (NASDAQ:VCNXFree Report).

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.